Education Use Only
For educational use only — Not for clinical decision-making without independent verification
Medical Associates  ·  Department of Nephrology ← urinenephrology.org
Nephrology Education Series

Hyperkalemia Treatment Report

Andrew Bland, MD, FACP, FAAP UICOMP · UDPA · Butler COM 2025-01-01 30 min read

COMPREHENSIVE REVIEW OF HYPERKALEMIA TREATMENT

Author: [Your Institution]
Date: April 6, 2025

Executive Summary

Hyperkalemia is a potentially life-threatening electrolyte disorder characterized by elevated serum potassium levels (>5.5 mEq/L). This comprehensive review examines the multifaceted approach to hyperkalemia management, focusing on cardiac membrane stabilization, intracellular potassium shifting, and potassium removal strategies. The review assesses the efficacy, onset of action, duration of effect, and safety profiles of various treatment modalities, including intravenous calcium, insulin-glucose therapy, beta-agonists, exchange resins, and dialysis. Special attention is given to practical challenges in treatment implementation and potentially reversible causes such as urinary obstruction. Newer potassium binders, including patiromer and sodium zirconium cyclosilicate, are compared with traditional sodium polystyrene sulfonate, highlighting their improved safety profiles for chronic management. This review synthesizes current evidence to provide clinicians with a structured approach to hyperkalemia management based on severity, ECG changes, and underlying comorbidities.

Table of Contents

  1. Introduction
  2. Treatment Strategy Overview
  3. Cardiac Membrane Stabilization
  4. Potassium Shifting Agents
  5. Potassium Removal Agents
  6. Practical Challenges of Initiating Dialysis
  7. Urinary Obstruction as a Cause of Hyperkalemia
  8. ECG Changes by Potassium Level
  9. Comparison of Potassium Exchange Resins
  10. Comparison of Potassium Removal Rates
  11. Clinical Implications and Recommendations
  12. Conclusion
  13. References

Introduction

Hyperkalemia represents one of the most common and potentially lethal electrolyte disorders encountered in clinical practice. Defined as a serum potassium concentration exceeding 5.5 mEq/L, hyperkalemia is particularly prevalent in patients with kidney disease, where incidence increases proportionally with declining glomerular filtration rate (GFR). The condition can be further exacerbated by medications that affect the renin-angiotensin-aldosterone system, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs).

The danger of hyperkalemia lies in its effects on cardiac electrophysiology, where elevated extracellular potassium alters the resting membrane potential of cardiac myocytes, potentially leading to life-threatening arrhythmias. Effective management requires a nuanced approach that addresses both the immediate risks to cardiac conduction and the underlying causes of potassium elevation.

This review provides a comprehensive examination of treatment strategies for hyperkalemia across the spectrum of severity, from mild asymptomatic elevations to emergency presentations with ECG abnormalities. The discussion encompasses the mechanisms of action, expected efficacy, time course, and safety profiles of available interventions, with particular attention to recent advances in pharmacological management and practical considerations in implementation.

Treatment Strategy Overview

The management of hyperkalemia follows a systematic and stepwise approach based on the severity of potassium elevation and the presence of clinical manifestations, particularly ECG changes. For severe hyperkalemia (potassium >7.0 mEq/L) or in patients with ECG abnormalities, treatment must begin promptly, even before a complete diagnostic investigation of the underlying cause.

The treatment paradigm encompasses three complementary strategies: 1. Stabilization of the cardiac membrane to reduce the risk of arrhythmias 2. Redistribution of potassium from the extracellular to the intracellular space 3. Elimination of potassium from the body

Concurrently, all sources of exogenous potassium should be immediately discontinued, including intravenous and oral potassium supplements, total parenteral nutrition, and blood product transfusions. Medications that impair potassium excretion or promote hyperkalemia should be reviewed and modified when possible.

The application of these strategies must be tailored to the individual patient, taking into account the acuity of presentation, underlying comorbidities, and institutional resources. The timing and selection of specific interventions depend on the clinical urgency, with simultaneous implementation of multiple approaches often necessary in severe cases.

Cardiac Membrane Stabilization

Calcium: Mechanism and Administration

Intravenous calcium serves as the cornerstone of initial management for severe hyperkalemia with ECG changes. Although calcium does not alter serum potassium levels, it rapidly antagonizes the cardiac membrane effects of hyperkalemia, effectively reducing the risk of potentially fatal arrhythmias.

The stabilizing effect of calcium on the cardiac membrane operates through two principal mechanisms: 1. Deposition of divalent calcium on the extracellular surface of cardiac myocytes creates a surface charge effect, resulting in partial repolarization of the membrane 2. Calcium may bind directly to voltage-gated sodium channels, promoting closure and allowing repolarization of the membrane potential

For clinical administration, either calcium chloride or calcium gluconate can be utilized, typically as 10 mL of a 10% solution infused over 2-3 minutes. The onset of action occurs within minutes, with a duration of effect lasting 30-60 minutes. This transient effect necessitates concurrent implementation of other strategies to reduce potassium levels.

It is imperative to note that calcium administration should be avoided in patients with suspected digoxin toxicity, as it can potentiate digitalis effects and exacerbate cardiac arrhythmias in this setting.

Comparison of Calcium Chloride and Calcium Gluconate

While both calcium chloride and calcium gluconate effectively stabilize the cardiac membrane in hyperkalemia, they differ substantially in their pharmacological properties, administration requirements, and clinical applications.

Calcium chloride contains approximately three times more elemental calcium than calcium gluconate for an equivalent volume of solution. Specifically, a 10 mL ampule of 10% calcium chloride provides 272 mg (13.6 mEq) of elemental calcium, compared to only 90 mg (4.5 mEq) in the same volume of 10% calcium gluconate. This difference in calcium content directly affects their potency in treating hyperkalemic cardiac effects.

The route of administration represents a critical distinction between these two formulations. Calcium chloride, owing to its high acidity (pH approximately 5.5-7.5), must be administered through a central venous catheter. Administration through peripheral veins carries a significant risk of severe tissue necrosis and sloughing if extravasation occurs. In contrast, calcium gluconate can be safely administered through peripheral venous access, making it the preferred agent when central access is not immediately available.

Calcium chloride delivers about three times more elemental calcium per ampule; this advantage can be offset by administering a higher dose of calcium gluconate (typically 30 mL of 10% solution compared to 10 mL of 10% calcium chloride).

The clinical selection between these agents should be guided by: - Clinical urgency: Calcium chloride provides faster action in cardiac arrest or severe manifestations when central access is available - Vascular access: Calcium gluconate is preferred with peripheral access only - Patient population: Calcium gluconate is generally preferred in pediatric patients for safety considerations - Clinical setting: Intensive care units may favor calcium chloride for its higher calcium content per volume when central access exists, while general wards typically use calcium gluconate for its safer administration profile

Potassium Shifting Agents

Insulin and Glucose

Insulin represents one of the most reliable and effective agents for rapidly shifting potassium from the extracellular to the intracellular compartment. It operates by binding to cell surface receptors and triggering increased activity of the Na⁺-K⁺-ATPase pump, facilitating the movement of potassium ions into cells.

The standard protocol involves administration of intravenous regular insulin, which demonstrates an onset of action within 15 minutes, reaches peak effect at 30-60 minutes, and maintains efficacy for approximately 4 hours. This contrasts with subcutaneous insulin, which has a delayed onset (approximately 30 minutes), later peak effect (3 hours), and longer duration (8 hours). The more rapid kinetics of the intravenous route make it the preferred method in acute hyperkalemia.

To prevent iatrogenic hypoglycemia, concurrent administration of glucose is essential, particularly in patients who are not hyperglycemic. The typical regimen includes 50 mL of 50% dextrose solution (25 grams of glucose) with 10 units of regular insulin. Patients with blood glucose levels >250 mg/dL may not require additional glucose, but close monitoring remains essential.

The risk of hypoglycemia deserves special consideration in patients with kidney disease, who exhibit increased susceptibility due to decreased gluconeogenesis and reduced insulin degradation. In such patients, more conservative insulin dosing (5 units) with equivalent glucose and more frequent blood glucose monitoring may be appropriate.

Beta-Agonists

Beta-2 adrenergic agonists, particularly albuterol, provide an alternative or complementary approach to shifting potassium intracellularly. These agents stimulate the Na⁺/K⁺-ATPase pump via beta-receptor activation, promoting potassium uptake into cells.

Inhaled beta-agonists demonstrate a rapid onset of action and can produce a reduction in serum potassium of 0.5-1.0 mEq/L. Importantly, the effect of beta-agonists is additive to that of insulin, making combination therapy particularly effective. The standard dose for this indication is 10-20 mg of nebulized albuterol, significantly higher than bronchodilator dosing.

An additional benefit of beta-agonists when used in combination with insulin is their potential to reduce the risk of hypoglycemia by promoting hepatic gluconeogenesis. However, their application may be limited in patients with coronary artery disease or certain arrhythmias due to the risk of tachycardia, palpitations, and potential myocardial ischemia.

Sodium Bicarbonate

The role of sodium bicarbonate in hyperkalemia management has evolved considerably. Current evidence suggests limited efficacy in non-acidotic patients, and it is no longer broadly recommended as a primary intervention for hyperkalemia unless concurrent metabolic acidosis is present.

The mechanism by which bicarbonate may reduce serum potassium involves a complex interplay of pH-dependent shifts in the transcellular distribution of potassium, with alkalinization promoting intracellular movement. However, this effect appears modest and inconsistent, particularly in patients with normal acid-base status.

Furthermore, administration of large volumes of isotonic or hypertonic bicarbonate carries risk of hypernatremia, fluid overload, and paradoxical intracellular acidosis due to carbon dioxide generation, particularly in patients with respiratory insufficiency. These concerns further limit its utility in general hyperkalemia management.

Potassium Removal Agents

Potassium Exchange Resins

Cation exchange resins represent an important strategy for promoting gastrointestinal elimination of potassium. Three main resins are currently available, each with distinct characteristics and clinical applications.

Sodium Polystyrene Sulfonate (SPS, Kayexalate): This older exchange resin has historically dominated clinical practice since its introduction in the 1950s. SPS exchanges sodium for potassium in the gastrointestinal tract, primarily in the colon. Despite its widespread use, SPS has been associated with significant adverse effects, including colonic necrosis (particularly when administered with sorbitol), hypomagnesemia, and hypernatremia. The onset of action is relatively slow (approximately 2 hours), and administration typically requires multiple doses (every 6-8 hours) for significant potassium reduction.

Patiromer (Veltassa): Approved in 2015, patiromer represents a newer generation of potassium-binding resin that exchanges calcium for potassium. It demonstrates a slower onset of action (approximately 7 hours) compared to SPS, but offers advantages of once-daily dosing and improved safety profile. Patiromer has fewer gastrointestinal side effects and drug interactions compared to SPS, though hypomagnesemia remains a concern requiring monitoring. Clinical trials have demonstrated normalization of serum potassium in 76% of patients after 4 weeks of treatment, making it particularly suitable for chronic hyperkalemia management.

Sodium Zirconium Cyclosilicate (SZC, Lokelma): The most recently approved agent (2018), SZC has a unique crystalline structure that exchanges both sodium and hydrogen for potassium. It demonstrates a more rapid onset than patiromer, with measurable potassium reduction within 1 hour (0.4 mEq/L) and further reduction by 4 hours (0.7 mEq/L). SZC is typically administered as a loading dose (10g three times daily for 48 hours) followed by maintenance dosing. Clinical studies have shown efficacy in both acute and chronic hyperkalemia, though its sodium content may contribute to fluid retention in susceptible patients.

Risks of Colonic Perforation with Sodium Polystyrene Sulfonate

The association between SPS and serious gastrointestinal injury, particularly colonic perforation, represents a significant safety concern that has prompted increased scrutiny of this medication. Understanding the mechanisms, risk factors, and clinical implications of this complication is essential for appropriate clinical decision-making.

SPS causes gastrointestinal injury through several mechanisms: 1. Direct mucosal damage: The resin particles themselves can directly irritate and damage the intestinal mucosa, with SPS crystals identified in tissue samples from injured colonic segments 2. Sorbitol contribution: The historical combination with sorbitol as a cathartic agent appears particularly dangerous, as the osmotic effect can dehydrate intestinal tissues 3. Physical properties: SPS maintains its crystalline structure throughout the gastrointestinal tract, allowing accumulation in areas of stasis or narrowing 4. Binding properties: Beyond potassium, SPS can bind other cations including calcium and magnesium, potentially disrupting epithelial cell junction integrity

The spectrum of gastrointestinal injury associated with SPS ranges from mucosal inflammation to transmural necrosis and perforation. Clinical manifestations may include abdominal pain, distension, gastrointestinal bleeding, signs of peritonitis, or systemic sepsis.

Several patient populations demonstrate particular vulnerability to SPS-induced gastrointestinal injury: - Post-surgical patients with compromised gut motility - Renal transplant recipients on immunosuppression - Patients with uremia causing baseline mucosal fragility - Critically ill patients with hemodynamic instability or vasopressor use - Those with intestinal obstruction or reduced motility - Patients with pre-existing constipation

These risks have prompted regulatory warnings, including a 2009 FDA alert and subsequent 2011 recommendation against SPS use with sorbitol. Even without sorbitol, cases of SPS-associated colonic injury continue to be reported, suggesting intrinsic risks with the medication itself.

The availability of newer, safer potassium binders has led to recommendations that alternative agents be considered, particularly in high-risk patients. When SPS must be used, avoiding sorbitol, maintaining vigilance for gastrointestinal symptoms, and prompt discontinuation upon any sign of intestinal injury represent important safety measures.

Diuretics

In patients with preserved kidney function, loop diuretics can effectively enhance urinary potassium excretion. This approach, termed kaliuresis, utilizes the potassium-wasting properties of these medications to increase potassium elimination through the kidneys.

The effectiveness of diuretic therapy correlates directly with residual renal function and urine output. Higher diuretic doses and potentially combination diuretic regimens (e.g., loop plus thiazide) may be necessary in patients with more severe hyperkalemia or significant renal impairment.

It is important to note that diuretic-induced volume contraction can paradoxically worsen hyperkalemia through reduced distal tubular flow rate and enhanced proximal tubular reabsorption. Therefore, adequate volume status must be maintained, potentially through concurrent administration of non-potassium-containing intravenous fluids.

Dialysis

Hemodialysis represents the most efficient and definitive method for potassium removal in severe hyperkalemia, particularly in patients with significant kidney dysfunction. The procedure directly removes potassium from the bloodstream through diffusion across a semipermeable membrane against a potassium concentration gradient.

The efficacy of hemodialysis for potassium removal is substantial and rapid, with typical reduction of 1 mEq/L within 60 minutes and a total reduction of approximately 2 mEq/L after 3 hours of standard treatment. Factors influencing the rate and extent of potassium removal include dialysate potassium concentration, blood and dialysate flow rates, dialyzer characteristics, and treatment duration.

A significant consideration with hemodialysis is the post-treatment rebound phenomenon, wherein serum potassium rises again after dialysis: about 35% of the intradialytic fall returns within the first hour and about 70% by 6 hours. This occurs due to continued movement of potassium from the intracellular to extracellular space as equilibrium is re-established. Consequently, close monitoring and potentially additional interventions are necessary in the post-dialysis period.

For critically ill patients, continuous renal replacement therapy (CRRT) may be utilized instead of intermittent hemodialysis. While CRRT provides continuous clearance, the rate of potassium removal is substantially slower. The primary advantage lies in improved hemodynamic stability, making it preferable for patients with cardiovascular instability.

Practical Challenges of Initiating Dialysis

Despite the efficacy of dialysis in hyperkalemia management, several practical challenges can delay its implementation and impact patient outcomes. Understanding these barriers is essential for developing comprehensive treatment strategies that include appropriate temporizing measures. The times given below are practical estimates from clinical experience rather than measured study data, and they vary widely between institutions.

Vascular Access Placement

For patients without pre-existing dialysis access, establishing vascular access represents a significant time constraint:

  • Central venous catheter placement typically requires 15-45 minutes under optimal conditions but can take longer depending on patient anatomy, provider expertise, and institutional resources
  • Ultrasound guidance has improved first-attempt success rates, but setup time, operator availability, and technical challenges can still contribute to delays
  • Anatomical challenges such as obesity, venous anomalies, or previous vascular complications may necessitate alternative access sites and extended placement time
  • Consent and preparation, including obtaining informed consent, preparing the sterile field, and administering local anesthesia, adds 10-20 minutes before the procedure begins

Machine Setup and Initiation

Once vascular access is established, additional steps are necessary before effective dialysis can begin:

  • Machine preparation, including priming of dialysis lines and dialyzer, typically requires 20-30 minutes when performed by experienced personnel
  • Patient connection to the dialysis circuit and ensuring proper flow rates takes an additional 5-10 minutes
  • Anticoagulation decisions must be made and implemented to prevent circuit clotting, adding procedural complexity
  • Staff availability, particularly during off-hours, may cause delays ranging from minutes to hours in many centers

Time to Effective Potassium Removal

Once dialysis commences, potassium removal follows a predictable but not instantaneous course:

  • Initial reduction of serum potassium is steepest early: more than 1 mEq/L in the first 60 minutes, then a slower fall and a plateau after about 3 hours
  • Clearance pattern follows a curvilinear trajectory with rapid initial decline followed by a slower rate of reduction
  • Contributing factors to removal efficiency include dialysate flow rate, blood flow rate, dialyzer characteristics, and the potassium gradient
  • Rebound phenomenon requires anticipation and management to prevent recurrent hyperkalemia

Cumulative Time Considerations

The combined effect of these sequential steps results in substantial delays from recognition of severe hyperkalemia to effective potassium reduction:

  • Best-case scenario: Approximately 30-45 minutes from decision to effective potassium reduction with pre-existing access and optimal staffing
  • Typical scenario: 60-120 minutes from decision to effective potassium reduction in well-resourced settings
  • Challenging scenarios: Delays of 2-4 hours or more in resource-limited settings, during off-hours, or with complex patients

These inevitable delays underscore the critical importance of implementing temporizing measures, including calcium, insulin-glucose, and beta-agonists, while preparing for dialysis in severe hyperkalemia.

Urinary Obstruction as a Cause of Hyperkalemia

Urinary tract obstruction represents an important and potentially rapidly reversible cause of hyperkalemia that warrants special consideration in the diagnostic and management approach.

Incidence and Significance

The contribution of urinary obstruction to hyperkalemia varies across populations:

  • Post-renal (obstructive) causes account for a minority of acute kidney injury, but they are important because they are rapidly reversible
  • Obstruction is more common in older men, primarily because of prostatic hyperplasia
  • Patients with pelvic malignancies (cervical, bladder, or prostate cancer) are at particular risk of obstruction
  • Obstruction combined with medications that impair potassium excretion further raises the risk of severe hyperkalemia

Effectiveness of Foley Catheter Placement

Relief of urinary obstruction via catheterization can lead to rapid resolution of hyperkalemia:

  • In complete urinary retention with hyperkalemia, restoring urine flow lets renal potassium excretion resume, and potassium usually falls over the following hours; the size of the fall has not been well quantified
  • The retained volume and the duration of obstruction help gauge severity
  • Post-obstructive diuresis after relief can produce brisk urine output and rapid potassium excretion
  • Relief of obstruction treats the cause, but temporizing measures (calcium, insulin-glucose) are still needed for severe hyperkalemia or ECG changes while drainage takes effect

Clinical Recognition and Approach

Early recognition of urinary obstruction as an underlying cause of hyperkalemia is essential:

  • Clinical clues include lower abdominal discomfort, distention, diminished urinary output, and relevant risk factors such as prostatic enlargement or pelvic malignancy
  • Bedside bladder ultrasound can rapidly identify urinary retention; a large residual volume in a patient who reports recent voiding suggests obstruction
  • An elevated post-void residual may indicate partial obstruction contributing to hyperkalemia
  • Assess for urinary obstruction early in the evaluation of unexplained hyperkalemia, particularly in high-risk populations

Management of Post-Obstruction Care

After catheter placement, ongoing monitoring and management are essential:

  • Fluid status requires close monitoring to prevent volume depletion during post-obstructive diuresis, with fluid replacement potentially necessary for sustained high-volume output
  • Electrolyte monitoring at regular intervals during the first 24 hours after catheterization helps track improvement and identify any rebound hyperkalemia
  • Addressing underlying causes should proceed once acute hyperkalemia is controlled
  • Medication review with potential adjustment of drugs affecting potassium homeostasis helps prevent recurrence

ECG Changes by Potassium Level

Electrocardiographic (ECG) changes provide valuable guidance for assessing the severity and urgency of hyperkalemia. These alterations typically progress in a sequential pattern that correlates with increasing potassium levels, although significant individual variation exists.

Serum Potassium Level (mEq/L) ECG Changes
5.5-6.5 Tall, peaked T waves with narrow base (best seen in precordial leads); shortened QT interval; ST-segment depression
6.5-8.0 Prolonged PR interval; decreased P wave amplitude; widened QRS complexes
>8.0 Absence of P wave; progressive QRS widening; intraventricular/fascicular/bundle-branch blocks; sine wave pattern (merged QRS-T waves); ventricular fibrillation or asystole

Important caveats regarding ECG manifestations of hyperkalemia include:

  1. Serum potassium level may not correlate precisely with ECG changes, and patients with relatively normal ECGs can still experience sudden hyperkalemic cardiac arrest
  2. ECG changes depend not only on the absolute potassium level but also on the rate of increase, associated metabolic abnormalities, and concomitant medications
  3. The clinical impact of hyperkalemia can be magnified by medications affecting cardiac conduction, particularly AV-nodal blockers
  4. The BRASH syndrome (Bradycardia, Renal failure, AV-nodal blockers, Shock, Hyperkalemia) represents a particular clinical entity where the interplay of these factors produces effects disproportionate to the measured potassium level

Comparison of Potassium Exchange Resins

Parameter Sodium Polystyrene Sulfonate (Kayexalate) Patiromer (Veltassa) Sodium Zirconium Cyclosilicate (Lokelma)
Year of FDA Approval Used since 1950s 2015 2018
Exchange Ion Sodium Calcium Sodium and hydrogen
Onset of Action ~2 hours ~7 hours 1 hour (measurable effect)
Administration Frequency Every 6-8 hours Once daily Loading dose of 10g TID for 48 hours, then 10g QD
Efficacy Variable Normalized serum potassium in 76% of patients after 4 weeks In one study with dialysis patients, more patients maintained predialysis potassium compared to placebo (41.2% vs 1.0%)
Major Side Effects Colonic necrosis, hypomagnesemia, hypernatremia Hypomagnesemia, hypersensitivity reactions Edema, fluid overload
Drug Interactions Binds to many substances other than potassium Fewer drug interactions than Kayexalate Affects absorption of some medications
Recommended Use Acute situations requiring rapid potassium lowering Long-term management of chronic hyperkalemia Both acute and chronic management

Comparison of Potassium Removal Rates

Treatment Modality Onset of Action Duration of Effect Potassium Reduction Notes
Calcium (IV) Minutes 30-60 minutes No direct reduction Stabilizes cardiac membranes without affecting potassium levels
Insulin + Glucose (IV) 15 minutes ~4 hours 0.6-1.0 mEq/L Response rate lower (~40-50%) in end-stage kidney disease
Beta-agonists (inhaled) Rapid 2-4 hours 0.5-1.0 mEq/L Should not be used as monotherapy; additive effect with insulin
Sodium Bicarbonate Variable 1-2 hours Variable Most effective in patients with metabolic acidosis
Patiromer ~7 hours 24 hours (daily dosing) 0.65-1.23 mEq/L over 4 weeks Effectiveness depends on baseline potassium levels
Sodium Zirconium Cyclosilicate 1 hour: 0.4 mEq/L 4 hours: 0.7 mEq/L 24 hours (daily dosing) 0.23 mEq/L (single 8.4g dose) Can reach normokalemia in 72 hours in most patients
Hemodialysis Immediate Rebound within 24 hours 1 mEq/L within 60 min; 2 mEq/L within 180 min Rebound: about 35% of the fall by 1 hour, 70% by 6 hours
Foley Catheter for Obstruction Hours Variable Variable; not well quantified Effective only in cases of urinary obstruction

Clinical Implications and Recommendations

The recognition of potential delays in dialysis initiation and the effectiveness of addressing reversible causes have important clinical implications for hyperkalemia management:

  1. Early involvement of nephrology and dialysis teams upon identification of severe hyperkalemia, even while initiating medical therapies
  2. Systematic implementation of temporizing measures (calcium, insulin-glucose, beta-agonists) during preparation for definitive treatment
  3. Assessment for urinary obstruction early in the evaluation of unexplained hyperkalemia, particularly in at-risk populations
  4. Prioritization of vascular access placement by experienced operators when dialysis is indicated
  5. Development of standardized protocols for emergent dialysis to reduce institutional delays
  6. Continuous monitoring during transitions between treatment modalities
  7. Vigilance for potassium rebound following dialysis, particularly in the first 6-12 hours

Conclusion

The management of hyperkalemia requires a multifaceted approach tailored to the severity of potassium elevation, the presence of ECG abnormalities, and underlying patient characteristics. For acute, severe presentations, calcium administration for cardiac stabilization followed by insulin-glucose therapy represents the initial intervention, with hemodialysis serving as definitive treatment in refractory cases or patients with kidney failure. For chronic hyperkalemia, newer potassium binders offer improved safety profiles compared to traditional resins, potentially allowing continuation of beneficial medications like RAASi that may contribute to hyperkalemia.

Each treatment modality has specific onset and duration characteristics that must guide clinical decision-making and sequencing of interventions. The practical challenges in implementing dialysis highlight the importance of temporizing measures and consideration of potentially reversible causes such as urinary obstruction.

A comprehensive approach to hyperkalemia management should include: - Rapid assessment of severity through laboratory values and ECG changes - Immediate stabilization of cardiac membranes when indicated - Implementation of potassium redistribution strategies - Identification and management of underlying causes - Selection of appropriate potassium removal methods based on clinical context - Vigilant monitoring throughout the treatment course and appropriate transitions between modalities

By incorporating these principles into a structured management algorithm, clinicians can optimize outcomes in this potentially life-threatening electrolyte disorder.

References

  1. Abraham, S.C., Bhagavan, B.S., Lee, L.A., Rashid, A., & Wu, T.T. (2001). Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings. American Journal of Surgical Pathology, 25(5), 637-644. PubMed

  2. Ahmed, J., & Weisberg, L.S. (2001). Hyperkalemia in dialysis patients. Seminars in Dialysis, 14(5), 348-356. PubMed

  3. Augustine, J.J., Sandy, D., Seifert, T.H., & Paganini, E.P. (2004). A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF. American Journal of Kidney Diseases, 44(6), 1000-1007. PubMed

  4. Bianchi, S., Aucella, F., De Nicola, L., Genovesi, S., Paoletti, E., & Regolisti, G. (2019). Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. Journal of Nephrology, 32(4), 499-516. PubMed

  5. Blumberg, A., Roser, H.W., Zehnder, C., & Müller-Brand, J. (1997). Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium. Nephrology Dialysis Transplantation, 12(8), 1629-1634. PubMed

  6. Blumberg, A., Weidmann, P., & Ferrari, P. (1992). Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. Kidney International, 41(2), 369-374. PubMed

  7. Brass, P., Hellmich, M., Kolodziej, L., Schick, G., & Smith, A.F. (2015). Ultrasound guidance versus anatomical landmarks for internal jugular vein catheterization. Cochrane Database of Systematic Reviews, 1, CD006962. PubMed

  8. Cañas, A.E., Troutt, H.R., Jiang, L., Tonthat, S., Darwish, O., Ferrey, A., et al. (2023). A randomized study to compare oral potassium binders in the treatment of acute hyperkalemia. BMC Nephrology, 24(1), 89. PubMed

  9. Chaitman, M., Dixit, D., & Bridgeman, M.B. (2016). Potassium-binding agents for the clinical management of hyperkalemia. P & T, 41(1), 43-50. PubMed

  10. Clark, E.G., & Barsuk, J.H. (2014). Temporary hemodialysis catheters: recent advances. Kidney International, 86(5), 888-895. PubMed

  11. Dardik, A., Moesinger, R.C., Efron, G., Barbul, A., & Harrison, M.G. (2000). Acute abdomen with colonic necrosis induced by Kayexalate-sorbitol. Southern Medical Journal, 93(5), 511-513. PubMed

  12. Daugirdas, J.T., Blake, P.G., & Ing, T.S. (2015). Handbook of Dialysis (5th ed.). Wolters Kluwer Health.

  13. Davenport, A. (2011). What are the anticoagulation options for intermittent hemodialysis? Nature Reviews Nephrology, 7(9), 499-508. PubMed

  14. Dépret, F., Peacock, W.F., Liu, K.D., Rafique, Z., Rossignol, P., & Legrand, M. (2019). Management of hyperkalemia in the acutely ill patient. Annals of Intensive Care, 9(1), 32. PubMed

  15. Dheenan, S., & Henrich, W.L. (2001). Preventing dialysis hypotension: a comparison of usual protective maneuvers. Kidney International, 59(3), 1175-1181. PubMed

  16. European Association of Urology Guidelines. (2023). Management of non-neurogenic male LUTS. Retrieved from https://uroweb.org/guidelines/

  17. Gerstman, B.B., Kirkman, R., & Platt, R. (1992). Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. American Journal of Kidney Diseases, 20(2), 159-161. PubMed

  18. Ghani, K.R., Roghmann, F., Sammon, J.D., Trudeau, V., Sukumar, S., Rahbar, H., et al. (2014). Emergency department visits in the United States for upper urinary tract stones: trends in hospitalization and charges. Journal of Urology, 191(1), 90-96. PubMed

  19. Gruver, J., Al-Makki, A., & Shepler, B. (2023). Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials. Journal of Pharmacy & Pharmaceutical Sciences, 26, 11892. PubMed

  20. Harel, Z., Harel, S., Shah, P.S., Wald, R., Perl, J., & Bell, C.M. (2013). Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. American Journal of Medicine, 126(3), 264.e9-264.e24. PubMed

  21. Hasara, S., Dubey, J., Amatea, J., & Finnigan, N. (2023). Sodium polystyrene sulfonate versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in the emergency department. American Journal of Emergency Medicine, 65, 59-64. PubMed

  22. Haupt, H.M., & Hutchins, G.M. (1982). Sodium polystyrene sulfonate pneumonitis. Archives of Internal Medicine, 142(2), 379-381. PubMed

  23. Hollander-Rodriguez, J.C., & Calvert, J.F., Jr. (2006). Hyperkalemia. American Family Physician, 73(2), 283-290. PubMed

  24. Kovesdy, C.P., Regidor, D.L., Mehrotra, R., et al. (2007). Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clinical Journal of the American Society of Nephrology, 2(5), 999-1007. PubMed

  25. Lewis, J.L. (2019). Disorders of potassium concentration. Merck Manual Professional Version. Retrieved from https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/electrolyte-disorders/disorders-of-potassium-concentration

  26. Lexicomp. (2023). Calcium chloride and calcium gluconate. In Drug Information Handbook. Wolters Kluwer.

  27. Li, T., & Vijayan, A. (2014). Insulin for the treatment of hyperkalemia: a double-edged sword? Clinical Kidney Journal, 7(3), 239-241. PubMed

  28. Lillemoe, K.D., Romolo, J.L., Hamilton, S.R., Pennington, L.R., Burdick, J.F., & Williams, G.M. (1987). Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery, 101(3), 267-272. PubMed

  29. Long, B., Warix, J.R., & Koyfman, A. (2018). Controversies in management of hyperkalemia. Journal of Emergency Medicine, 55(2), 192-205. PubMed

  30. Marshall, M.R., Creamer, J.M., Foster, M., Ma, T.M., Mann, S.L., Fiaccadori, E., et al. (2011). Mortality rate comparison after switching from continuous to prolonged intermittent renal replacement for acute kidney injury in three intensive care units from different countries. Nephrology Dialysis Transplantation, 26(7), 2169-2175. PubMed

  31. McGowan, C.E., Saha, S., Chu, G., Resnick, M.B., & Moss, S.F. (2009). Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. Southern Medical Journal, 102(5), 493-497. PubMed

  32. Meaney, C.J., Beccari, M.V., Yang, Y., & Zhao, J. (2017). Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia. Pharmacotherapy, 37(4), 401-411. PubMed

  33. Mushiyakh, Y., Dangaria, H., Qavi, S., Ali, N., Pannone, J., & Tompkins, D. (2011). Treatment and pathogenesis of acute hyperkalemia. Journal of Community Hospital Internal Medicine Perspectives, 1(4). PubMed

  34. Noble, V.E., & Brown, D.F. (2004). Renal ultrasound. Emergency Medicine Clinics of North America, 22(3), 641-659. PubMed

  35. Packham, D.K., Rasmussen, H.S., Lavin, P.T., El-Shahawy, M.A., Roger, S.D., Block, G., Qunibi, W., Pergola, P., & Singh, B. (2015). Sodium zirconium cyclosilicate in hyperkalemia. New England Journal of Medicine, 372(3), 222-231. PubMed

  36. Palmer, B.F., & Clegg, D.J. (2024). Hyperkalemia treatment standard. Nephrology Dialysis Transplantation, 39(7), 1097-1104. PubMed

  37. Patel, I.J., Davidson, J.C., Nikolic, B., Salazar, G.M., Schwartzberg, M.S., Walker, T.G., et al. (2012). Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. Journal of Vascular and Interventional Radiology, 23(6), 727-736. PubMed

  38. Rafique, Z., Aceves, J., Espina, I., Peacock, F., Sheikh-Hamad, D., & Kuo, D. (2020). Can physicians detect hyperkalemia based on the electrocardiogram? American Journal of Emergency Medicine, 38(1), 105-108. PubMed

  39. Raffee, L.A., Alawneh, K.Z., Ababneh, M.J., Hijazi, H.H., Al Abdi, R.M., Aboozour, M.M., et al. (2022). Clinical and electrocardiogram presentations of patients with high serum potassium concentrations within emergency settings: a prospective study. International Journal of Emergency Medicine, 15(1), 23. PubMed

  40. Rashid, A., & Hamilton, S.R. (1997). Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition. American Journal of Surgical Pathology, 21(1), 60-69. PubMed

  41. Ricci, Z., Ronco, C., D’Amico, G., De Felice, R., Rossi, S., Bolgan, I., et al. (2006). Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrology Dialysis Transplantation, 21(3), 690-696. PubMed

  42. Roscioni, S.S., & Lambers Heerspink, H.J. (2015). Clinical trials: new nonabsorbable potassium-exchange resins in hyperkalaemia. Nature Reviews Nephrology, 11(4), 205-206. PubMed

  43. Sterns, R.H., Rojas, M., Bernstein, P., & Chennupati, S. (2010). Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? Journal of the American Society of Nephrology, 21(5), 733-735. PubMed

  44. Tolwani, A. (2012). Continuous renal-replacement therapy for acute kidney injury. The New England Journal of Medicine, 367(26), 2505-2514. PubMed

  45. Topjian, A.A., Raymond, T.T., Atkins, D., Chan, M., Duff, J.P., Joyner, B.L., Jr., et al. (2020). Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation, 142(16 Suppl 2), S469-S523. PubMed

  46. U.S. Food and Drug Administration. (2009, 2011). Kayexalate (sodium polystyrene sulfonate) powder: prescribing information, revised April 2009 (concomitant sorbitol implicated in colonic necrosis) and 2011 (strengthened intestinal necrosis warning). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/011287s021lbl.pdf and https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011287s023lbl.pdf

  47. Varga, C., Kálmán, Z., Szakáll, A., Drubits, K., Koch, M., Bánhegyi, R., et al. (2019). ECG alterations suggestive of hyperkalemia in normokalemic versus hyperkalemic patients. BMC Emergency Medicine, 19(1), 33. PubMed

  48. Weir, M.R., Bakris, G.L., Bushinsky, D.A., Mayo, M.R., Garza, D., Stasiv, Y., Wittes, J., Christ-Schmidt, H., Berman, L., & Pitt, B. (2015). Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. New England Journal of Medicine, 372(3), 211-221. PubMed

  49. Hyperkalemia treatment & management. (n.d.). Medscape Reference. Accessed 2025. Retrieved from https://emedicine.medscape.com/article/240903-treatment

  50. Hyperkalemia: practice essentials, background, pathophysiology. (n.d.). Medscape Reference. Accessed 2025. Retrieved from https://emedicine.medscape.com/article/240903-overview

  51. Hyperkalemia workup: approach considerations, potassium assay, electrocardiography. (n.d.). Medscape Reference. Accessed 2025. Retrieved from https://emedicine.medscape.com/article/240903-workup

  52. Treatment and prevention of hyperkalemia in adults. (n.d.). UpToDate. Accessed 2025. Retrieved from https://www.uptodate.com/contents/treatment-and-prevention-of-hyperkalemia-in-adults

  53. Hyperkalemia (high potassium). (2023). National Kidney Foundation. Retrieved from https://www.kidney.org/kidney-topics/hyperkalemia-high-potassium

  54. Best practices in managing hyperkalemia in chronic kidney disease. (n.d.). National Kidney Foundation. Accessed 2025. Retrieved from https://www.kidney.org/sites/default/files/02-10-7259_DBH_Best-Practices-in-Managing-Hyperkalemia-in-CKD.pdf

  55. Hyperkalemia (high potassium): symptoms & treatment. (2023). Cleveland Clinic. Retrieved from https://my.clevelandclinic.org/health/diseases/15184-hyperkalemia-high-blood-potassium

  56. Episode 34: Severe hyperkalemia treatment. (2017). Pharmacy Joe. Retrieved from https://pharmacyjoe.com/severe-hyperkalemia-treatment-protect-the-heart-hide-the-potassium-remove-it/

  57. Hyperkalaemia ECG changes. (2024). Life in the Fast Lane. Retrieved from https://litfl.com/hyperkalaemia-ecg-library/

  58. Hypokalaemia ECG changes. (2024). Life in the Fast Lane. Retrieved from https://litfl.com/hypokalaemia-ecg-library/

  59. Hyperkalemia ECG review. (2015). Healio. Retrieved from https://www.healio.com/cardiology/learn-the-heart/ecg-review/ecg-topic-reviews-and-criteria/hyperkalemia-review

  60. ECG Cases 10: hyperkalemia. (2020). EM Cases. Retrieved from https://emergencymedicinecases.com/ecg-cases-10-hyperkalemia-the-great-imitator/

  61. Hyperkalemia. (2024). EMCrit Project (Internet Book of Critical Care). Retrieved from https://emcrit.org/ibcc/hyperkalemia/

  62. Updated treatment options in the management of hyperkalemia. (2017). US Pharmacist. Retrieved from https://www.uspharmacist.com/article/updated-treatment-options-in-the-management-of-hyperkalemia

Educational Resources

  • Student Handout: Hyperkalemia — PA/medical student educational guide

Also on this topic

The same subject at other levels of depth.